glucose

Monitoring Patient Glucose Levels: New Advances in software make it easier

Monitoring patient glucose levels and determining the response to interventio... U.S. and the UK1. Self- monitoring by patients of glucose levels, and the data provided is especially important for patients with a history of brittle diabete...

Analyzers Offer Point-of-Care Lipid Panels

...ample analyzers are highly flexible, incorporating glucose testing with various lipid panels and, in one devi...r to perform total cholesterol (150-300 mg/dL) and glucose (20-600 mg/dL) with the same system. This simple, CLIA-waived test provides total cholesterol result...

Tight Glycemic Control in the ICU

...ongoing debate and research on what level of blood glucose is optimal, and whether the benefits to patients r...tion include worry about hypoglycemia, accuracy of glucose meters, and increased nursing work-load. Clinicians in units with TGC report that with close monito...

Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control

...2, and gestational) marked by high levels of blood glucose resulting from defects in insulin production, insu...1c, as the best way to determine a patient's blood glucose control over the past 2-3 months. Specifically, the test measures the concentration of glycosylated ...

CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa

...els of insulinresistance, ranolazine also improved glucose homeostasis. These data could illustrate an underlying first in classmechanism of action for the statistically significant reductions inHbA1c levels observed with Ranexa in cardiovascular patients withdiabetes from the phase 3 CARISA (n=189 with ang...

A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients

...E1-I.N.T.(TM), showedsustained reductions in blood glucose control parameters, includinghaemoglobinA1C (HbA1c...the study. "Achieving sustained improvements in glucose control for manymonths post-treatment following a 4-week therapy is unprecedentedin type 2 diabetes....

Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice

...e studies also demonstrated thatMDIs function in a glucose responsive manner when transplanted intodiabetic a...prolonged reduction(greater than 60 days) in blood glucose levels when MDIs weretransplanted under the kidney capsule of stz-induced NOD/SCIDmice. The secon...

Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone

... statistically significantly reducedfasting plasma glucose (secondary endpoint) as compared toplacebo+metform...emia in each of the four arms (as measured byblood glucose less than or equal to 50 mg/dL with symptoms). Themost common adverse events seen in more than 5 per...

Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone

... statistically significantly reducedfasting plasma glucose (secondary endpoint) as compared toplacebo+metform...emia in each of the four arms (as measured byblood glucose less than or equal to 50 mg/dL with symptoms). Themost common adverse events seen in more than 5 per...

An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes

...called theincretin system, which helps to regulate glucose by affecting thebeta cells and alpha cells in the ...nto static (beta cell responsivenessto above-basal glucose following a meal) and dynamic (beta cellresponsiveness to the rate of increase in above-basal glucos...

New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir

...® dose every three days based on fastingplasma glucose (FPG)] or “Standard-of-Care”(Levemir&r...at the average A1c, an indicator of long-termblood glucose control, decreased from 8.5 percent at baseline to7.9 percent at 26 weeks for the 303 Algorithm grou...

First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes

...uced fasting serumglucose (FSG) and post challenge glucose excursion in subjects withType 2 diabetes. The da...s of the study included assessing the fastingserum glucose and post challenge glucose excursion. Thepresentation, "Dapagliflozin, a Selective Inhibitor of theS...

Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target

...ontrol (A1c) byreducing both fasting and post-meal glucose levels in people withtype 2 diabetes. The Phase 2 ...n insulin sensitivity, isthat they can lower blood glucose levels, resulting inhypoglycemia, which can sometimes be dangerous," said ProfessorYutaka Seino, Dir...

Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes

...ar risk factorsapart from its influence on fasting glucose level." "With the favorable conclusion of this la...atment withCycloset(TM) may improve hyperglycemia, glucose intolerance,hyperlipidemia, or aspects of insulin resistance, while maintainingbody fat neutrality o...

Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes

...red by A1C (-0.8+/- 0.1 percent) and fasting blood glucose (-24 +/- 4 mg/dL),consistent with findings from pr...rcent).(1,2) "The sustained improvements in blood glucose control and thesecondary benefits of progressive weight loss seen with BYETTA arewell documented," s...

Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes

...called theincretin system, which helps to regulate glucose by affecting thebeta cells and alpha cells in the ...12 vs. 9),hypoglycemia (9 vs. 58), increased blood glucose (5 vs. 9),osteoarthritis (2 vs. 1), contact dermatitis (1 vs. less than 1),tremor (1 vs. less than 1...

New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes

... glimepiridealone[2]. HbA1c is a measure of plasma glucose levels over thepreceding three months, and indicates how well diabetes is beingcontrolled over time. These data supplement existing findings with Galvus when used incombination with widely prescribed diabetes medicines such asmetformin, an oral thia...

New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir

...ir(R) dose every threedays based on fasting plasma glucose (FPG)] or "Standard-of- Care"(Levemir(R) dose was ...at the average A1c, an indicator of long-termblood glucose control, decreased from 8.5 percent at baseline to7.9 percent at 26 weeks for the 303 Algorithm grou...

Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA

...of DPP-4 andproduced superior reductions in plasma glucose compared withsitagliptin in oral glucose tolerance test (OGTT) in mice.Additionally, ARI-2243 produced significant reduction in hemoglobinA1c...

Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session

...orbidities associated with obesity such asabnormal glucose metabolism and cholesterol elevation. About Genaera Genaera Corporation is focused on advancing the science andtreatment of metabolic diseases. The Company has significant marketopportunities with a first-in-class molecule, trodusquamine (orMSI-143...

Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Association's Annual Meeting

...tably decreasing body weight, improvements inblood glucose and insulin levels, and reductions in fatty liver....tshowed decreased body weight, as well as improved glucose andinsulin control compared to the mice treated with vehicle. Inaddition, GhrR antagonist treatment ...

Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting

...fter anovernight insulin drip to maintain standard glucose levels. Eachpatient received a 450 calorie high-protein boost challenge afterthe study drug was administered. Researchers also presented results from two additionalBentley-sponsored studies to determine if smoking had any effect onthe absorption o...

Elixir Pharmaceuticals Announces Clinical Data at American Diabetes Association Conference Highlighting Ability of Glufast to Maintain Glycemic Control in Patients with Type 2 Diabetes

...y, or combination therapy with metformin, tomanage glucose surges before and after meals. The data werepublis...n secretagogue that lowers postprandial(post-meal) glucose levels by improving the body's own ability toproduce insulin. Marketed in Japan since 2004, Glufast ...

Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinson's Disease

...vement also correlated well to metabolicchanges in glucose utilization as measured by PET scan. The PETscan data revealed a significant improvement (p less than 0.001) inbrain metabolism on the treated side of the brain compared to theuntreated side. No adverse events related to the gene therapyprocedure wer...

MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions

...iently use the insulin itproduces to control blood glucose levels. ACTOS is taken once dailyas an adjunct to ...e fortype 2 diabetes as monotherapy to lower blood glucose and incombination therapy with insulin, sulfonylureas or metformin. Additional Information ACTOS i...

Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study

...ogramme, showing thatliraglutide provides improved glucose control compared to insulinglargine while, at the ...und3,800 patients with type 2 diabetes whose blood glucose isinadequately controlled. HbA1c is an abbreviation for glycated haemoglobin HbA1c. The levelof Hb...

ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting

...nt groupsexperienced reductions in fasting plasma glucose that werestatistically significant versus baseline...ed rapidand long-lasting reductions in mean daily glucose and fastingplasma glucose levels, persisting for at least 7 days afterthe single injection. In a s...

Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions

...orbidities associated with obesity suchas abnormal glucose metabolism and cholesterol elevation. About Genaera Genaera Corporation is focused on advancing the science andtreatment of metabolic diseases. The Company has significant marketopportunities with a first-in-class molecule, trodusquemine (orMSI-143...

Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy

...t worse. People who have diabetes and use a blood glucose monitor tocheck their sugar levels should tell their doctor. The infusion ofORENCIA contains maltose, a sugar that can give falsely high bloodglucose readings with some monitors on the day the infusion isreceived. The doctor may recommend a different...

Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimer's Disease at International Conference on Prevention of Dementia

...who also exhibited a genetic variation thataffects glucose regulation showed a 5-point improvement in ADAS-Cogscores compared to placebo, providing further insight into thedisease. As in the double-blind phase of the study, the most profoundeffect was seen in subjects not expressing the ApoE4 genotype, agen...

Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control

...t mice, the antagonist-treatedmice showed improved glucose and insulin control compared to themice treated wi... presentations, has shown it ispossible to improve glucose control, decrease fat, including in theliver, and to regulate metabolism through the inhibition ofgh...

Theratechnologies: TH9507 Phase 3 Clinical Update

...se tissue (fat containing tissue),dyslipidemia and glucose intolerance. The changes in fatdistribution include visceral fat accumulation and/or loss ofsubcutaneous fat, generally in the limbs and in the face. There isno treatment available for the accumulation of visceral fat foundin patients with HIV-associ...

Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting

...t cancer cells exhibit higher-than-normallevels of glucose uptake and, therefore, show up clearly as brightspots on PET images. Oncologists often use PET scans to detecttumors, or to examine the effects of a cancer therapy by measuringthe metabolic activity of the cancer cell before and aftertreatment. Stand...

Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia

...with diabetes should be monitored for worsening of glucose control; those with risk factors for diabete... undergo baseline and periodic fasting blood glucose testing. Patients who develop symptoms of hyperglycemia should also undergo fasting blood gluc...

Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)

...uing the discovery of newmedicines in the areas of glucose metabolic disorders, infectiousdiseases, cancer, bone and joint diseases, and immunedisorders. <p style="MARGIN: 0in 0in 0pt; LINE-HEIGHT: 150%; mso-layout-grid-align: none"> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in; LINE-HEIG...

Blood Levels of Paliperidone Extended-Release Tablets are Not Increased by Common Antidepressant

... at riskfor diabetes, should undergo fasting blood glucose testing at thebeginning of and during treatment. Patients who develop symptoms ofhyperglycemia should also undergo fasting blood glucosetesting. Gastrointestinal: Paliperidone should ordinarily not beadministered to patients with pre-existing severe...

New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia

...e at risk fordiabetes should undergo fasting blood glucose testing at thebeginning of and during treatment. P...ding SEROQUEL.The relationship of atypical use and glucose abnormalities iscomplicated by the possibility of increased risk of diabetes in theschizophrenic pop...

New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia

...g degrees, some may be associated with weightgain, glucose and lipid abnormalities, which may increase the riskof diabetes and heart disease. These side effects are compounded bythe fact that individuals with schizophrenia are more likely thanthe general population to be overweight or obese, and they have ah...

Six-Week Investigational Study In Adults With Major Depressive Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole Therapy With Antidepressants

...with diabetes should be monitored for worsening of glucose control; those with risk factors for diabete... undergo baseline and periodic fasting blood glucose testing. Patients who develop symptoms of hyperglycemia should also undergo fasting blood gluc...

Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy

...ment groups. No clinically significant changes in glucose or lipids were seen with nebivolol monotherapy during the study. -- "Addition of the Beta-Blocker Nebivolol to Ongoing Therapy in the Management of Mild-to-Moderate Hypertension" by Alan H. Gradman, MD, Chief, Division of Cardiov...

Positive Statistical Analysis from Synthetic Blood's Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint

...eline was met. Data also show adecrease in patient glucose and lactate/pyruvate (LP) ratio,consistent with increased glucose metabolism. Patients in thistrial were stabilized with either 50% or 100% oxygen. Datadetermined tha...

Accera, Inc. Announces Results of Phase II Study in Alzheimer's Disease at American Academy of Neurology Meeting

...who also exhibited a geneticvariation that affects glucose regulation showed a 5 pointimprovement in ADAS-Cog...vidence of thelink between Alzheimer's disease and glucose metabolism." Regardless of genotype, subjects treated with AC-1202 showed atrend toward improvement...

Insmed Releases Positive Results from Iplex Phase II HIV-Associated Adipose Redistribution Syndrome Clinical Study

...associated with significant improvements infasting glucose levels, the amount of insulin secreted during anoral glucose tolerance test, and overall insulin sensitivity.Moreover, there was a significant reduction in trunk...

Researchers Identify New Genetic Risk Factors for Type 2 Diabetes

...type 2 diabetes and theother half had normal blood glucose levels. “We thank all the Finnish citize... the healthy groupexcluded people who had impaired glucose tolerance or impairedfasting glucose. For more information about genome-wide associationstudies, g...

New Data Show Xenical Significantly Reduces Cardiovascular Risk and More Than Doubles Weight Loss Achieved in Overweight and Obese People

... 8.7%receiving placebo (p(less than)0.05) - Blood glucose levels - HbA1c (-0.41% vs. -0.03%, p(lessthan)0.00...l/l vs. -14.17 pmol/l, p(lessthan)0.01) - Fasting glucose (-1.23 mmol/l vs. -0.38mmol/l, p(lessthan)0.0001) - Total cholesterol (-4.19% vs. 0.77%, p(less tha...

Baxter Presents Phase I Inhaled Insulin Study Results at Respiratory Drug Delivery Conference

...C(time to reach 10 percent of total area under the glucose infusionrate (GIR) curve 73 vs 95 min.; GIR-tmax 173 versus 218 min.,p<0.0001). Duration of action (371 vs 366 min.) and totalmetabolic effect (GIR-AUC0-10h of 2,734 vs 2,482 mg/kg) werecomparable. Pharmacokinetic results were in accordance with ...

GTx Announces Ostarine Improved Insulin Resistance among Elderly Patients in a Recently Completed Phase II Clinical Trial

...d 60 postmenopausalwomen revealed that insulin and glucose levels were reduced andinsulin resistance was impr...=23) had on average an 11%decline in fasting blood glucose (p less than 0.001), a 17.6%reduction in insulin levels (p=0.043), and a 26.8% reduction ininsulin r...

Arrowhead Subsidiaries Insert & Calando Present Data on Cyclosert Drug Delivery System at AACR Meeting

... body. Basedon small cyclic repeating molecules of glucose calledcyclodextrins, Cyclosert promotes the ability of cytotoxic drugs toinhibit the growth of human cancer cells while reducing toxicityand remaining non-immunogenic at therapeutic doses. In particular,the system is designed to reduce the toxicity o...

Poster on Cyclosert Drug Delivery Presented at AACR Meeting

... body. Basedon small cyclic repeating molecules of glucose calledcyclodextrins, Cyclosert promotes the ability of cytotoxic drugs toinhibit the growth of human cancer cells while remaining non-toxicand non-immunogenic at therapeutic doses. In particular, the systemis designed to keep the drugs non-toxic unti...

First-of-its-Kind National Report Reveals Estimated High Prevalence and Heavy Cost of Type 2 Diabetes Complications in America

... 2 diabetes need to achieveand maintain good blood glucose levels over time to improve theirchances of reducing the risk of these serious complications." The State of Diabetes Complications in America reportsynthesizes data from two large national studies to examine theissue of diabetes-related complication...

New Data Confirm That Use of Levemir Can Limit Weight Gain

...nly animprovement in patients’ average blood glucose levels, butalso a decrease in their average body w...ulin,Levemir® causes less fluctuation in blood glucose levels acrossthe day and has greater predictability, ie a blood glucose loweringeffect that is consi...

Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo

...g degrees, some may be associated with weightgain, glucose and triglyceride elevations, and altered lipids,which may increase the risk of diabetes and heart disease. Theseside effects are compounded by the fact that individuals withschizophrenia are more likely than the general population to beoverweight or ...

PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results Demonstrate Safety and Efficacy at Once-Weekly Dosing

...gauge needle. Reductions in mean fasting plasma glucose (FPG) werestatistically significant in all treatme...very well toleratedand effective in lowering blood glucose levels." ConjuChem intends to submit the study results for presentationat a scientific meeting in 2...

Survey Reveals Significant Public Lack of Diabetes Awareness

...s productsinclude insulin pump therapy, continuous glucose monitoringsystems, related disposable products and diabetes managementsoftware. In March 2007, Medtronic received FDA approval forpediatric use of its CGM systems for children and teenagers ages7-17, marking a fundamental shift in children's ability ...

Nearly 1 in 10 Americans Has A Relative With Kidney Failure

...r kidney disease risk factors,including high blood glucose (sugar) levels and especiallyobesity. African-Americans who had a relative with ESRD were at increasedrisk of having reduced kidney function themselves. The levels ofimpairment were similar to those leading to the diagnosis ofchronic kidney disease ...

Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success

... medication experienced significant improvementsin glucose control and weight as well as in HDL cholesterol andtriglycerides. Importantly, about 57 % of the improvements in HbA1Cwere independent of the weight loss achieved. The mechanism of action of CB1 antagonists still is not yetfully understood. Data in...